All In MedTech

Device Trial Radar · NCT06190054

Evaluation of Performance and Safety of Eye Drops With Hydroxypropyl-methylcellulose and Inositol in Drye Eye Disease

Evaluation of the Efficacy and Safety of an Eye Drops With Hydroxypropyl-methylcellulose and Inositol as Principal Components (MERAMIRT®) in the Treatment of Dry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal Users

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Feb 6, 2023

Primary completion

Jan 3, 2025

Study completion Mar 4, 2025

Sponsor

Lead sponsor
Fidia Farmaceutici s.p.a.Not on our public-company list
Sponsor type
Industry
First posted
Jan 5, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a profit, multicentric, prospective, single-arm, open-label, non-pharmacological clinical investigation. Patients with diagnosis of moderate to severe dry eye disease with asthenopia and accommodative effort will receive MERAMIRT®, 1-2 drop per eye 3 times a day for 90 days.

Conditions

  • Dry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal Users

Interventions

  • MERAMIRTDevice

    MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%). HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Assessment of dry eye symptoms from baselineTime frame: Day 30

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • ASST Bergamo Est-Ospedale M.O.A. Locatelli

    Piario, Bergamo, Italy

  • Fondazione Policlinico Universitario Campus Biomedico

    Roma, RO, Italy

  • AOU- San Giovanni di Dio e Ruggi d'Aragona

    Salerno, Salerno, Italy

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.